Please login to the form below

Not currently logged in
Email:
Password:

Cephalon CEO on leave

Cephalon CEO Frank Baldino is taking a leave of absence, with his duties being temporarily transferred to chief operating officer J Kevin Buchi

Cephalon chairman and CEO Frank Baldino is taking a medical leave of absence, with his responsibilities being temporarily transferred to chief operating officer J Kevin Buchi. The biotech company hopes that Baldino will return later this year and declined to comment on his medical condition.

Baldino, who founded the company, is 56 years old. He has been Cephalon's CEO since the company was launched 20 years ago and became chairman of the board in 1999. Under Baldino's leadership, Cephalon has launched eight products in the US and has earned a place on the Fortune 1000 annual ranking of America's largest corporations.

Before founding Cephalon, Baldino was a senior research biologist in the medical products department at EI duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He holds a PhD in pharmacology from Temple University.

Buchi was tapped to fill the newly-created role of chief operating officer earlier this year, after a 20-year tenure with the firm that included 14 years as chief financial officer.  He joined Cephalon as controller in March 1991 and held several financial positions before being appointed chief financial officer. Earlier in his career, he held a number of financial positions with EI duPont de Nemours.

26th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics